# Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis

> **NCT03591094** · PHASE2 · COMPLETED · sponsor: **Proteostasis Therapeutics, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** PTI-428
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03591094
- **Lead sponsor:** Proteostasis Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-21
- **Primary completion:** 2019-02-18
- **Final completion:** 2019-02-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591094, "Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03591094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*